"Thiazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms.
| Descriptor ID |
D013844
|
| MeSH Number(s) |
D02.886.675 D03.383.129.708
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazoles".
Below are MeSH descriptors whose meaning is more specific than "Thiazoles".
This graph shows the total number of publications written about "Thiazoles" by people in this website by year, and whether "Thiazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1999 | 2 | 2 | 4 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 3 | 4 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 4 | 5 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 4 | 0 | 4 |
| 2010 | 4 | 2 | 6 |
| 2011 | 5 | 1 | 6 |
| 2012 | 4 | 0 | 4 |
| 2013 | 4 | 5 | 9 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 4 | 5 |
| 2016 | 1 | 3 | 4 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 1 | 2 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiazoles" by people in Profiles.
-
Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study. Lancet Haematol. 2025 Jul; 12(7):e494-e504.
-
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019 Aug; 180:37-42.
-
Nitazoxanide Is a Therapeutic Option for Adenovirus-Related Enteritis in Immunocompromised Adults. Antimicrob Agents Chemother. 2018 12; 62(12).
-
Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience. Pediatr Obes. 2017 08; 12(4):337-345.
-
Identification of Candidate Cyclin-dependent kinase 1 (Cdk1) Substrates in Mitosis by Quantitative Phosphoproteomics. Mol Cell Proteomics. 2016 07; 15(7):2448-61.
-
The evolving role of dabigatran etexilate in clinical practice. Expert Opin Pharmacother. 2015; 16(13):2053-72.
-
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
-
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3.
-
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
-
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 Oct 15; 5(19):9049-64.